Accessibility Menu
Citius Pharmaceuticals logo

Citius Pharmaceuticals

(NASDAQ) CTXR

Current Price$0.60
Market Cap$16.60M
Since IPO (2014)-100%
5 Year-99%
1 Year-62%
1 Month-8%

Citius Pharmaceuticals Financials at a Glance

Market Cap

$16.60M

Revenue (TTM)

$5.61M

Net Income (TTM)

-$46.20M

EPS (TTM)

-$2.57

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$0.60

Volume

172,638

Open

$0.59

Previous Close

$0.60

Daily Range

$0.57 - $0.61

52-Week Range

$0.48 - $2.48

Estimated Earnings Date

Aug 11, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Citius Pharmaceuticals

Industry

Pharmaceuticals

Employees

23

CEO

Leonard L. Mazur, MBA

Headquarters

Cranford, NJ 07016, US

CTXR Financials

Key Financial Metrics (TTM)

Gross Margin

37.36%

Operating Margin

-1041.44%

Net Income Margin

-823.34%

Return on Equity

-67.42%

Return on Capital

-55.54%

Return on Assets

-34.86%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.60M

Shares Outstanding

27.45M

Volume

172.64K

Avg. Volume

654.30K

Financials (TTM)

Gross Profit

$2.10M

Operating Income

-$58.44M

EBITDA

-$55.93M

Operating Cash Flow

-$31.60M

Capital Expenditure

$4.00

Free Cash Flow

-$31.60M

Cash & ST Invst.

$4.59M

Total Debt

$808.16K

Citius Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.67M

N/A

Gross Profit

-$381.89K

N/A

Gross Margin

-22.90%

N/A

Market Cap

$16.60M

N/A

Market Cap/Employee

$721.53K

N/A

Employees

23

N/A

Net Income

-$21.23M

-94.5%

EBITDA

-$30.43M

-171.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.59M

+17280.4%

Total Debt

$808.16K

-13.3%

Accounts Receivable

$1.08M

N/A

Inventory

$22.66M

+47.7%

Long Term Debt

$636.67K

-19.1%

Short Term Debt

$171.50K

+18.2%

Return on Assets

-34.86%

N/A

Return on Invested Capital

-75.38%

N/A

Free Cash Flow

-$1.30M

+71.4%

Operating Cash Flow

-$1.30M

+71.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBRXMoleculin Biotech, Inc.
$2.79-21.85%
LNAILunai Bioworks Inc.
$3.27+3.15%
DAREDare Bioscience, Inc.
$2.11+0.48%
ICUSeaStar Medical Holding Corporation
$3.67+3.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$139.80+0.06%
NVDANvidia
$200.16+0.03%
NKENike
$41.07-0.01%
AAPLApple
$289.34+0.03%

Questions About CTXR

What is the current price of Citius Pharmaceuticals?

Citius Pharmaceuticals is trading at $0.60 per share.

What is the 52-week range for Citius Pharmaceuticals?

Over the past 52 weeks, Citius Pharmaceuticals has traded between $0.48 and $2.48.

How much debt does Citius Pharmaceuticals have?

As of the most recent reporting period, Citius Pharmaceuticals reported total debt of $808.16K.

How much cash does Citius Pharmaceuticals have on hand?

Citius Pharmaceuticals reported $4.59M in cash and cash equivalents in its most recent financial results.

What is Citius Pharmaceuticals’s dividend yield?

Citius Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.